MXPA00011248A - Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. - Google Patents

Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.

Info

Publication number
MXPA00011248A
MXPA00011248A MXPA00011248A MXPA00011248A MXPA00011248A MX PA00011248 A MXPA00011248 A MX PA00011248A MX PA00011248 A MXPA00011248 A MX PA00011248A MX PA00011248 A MXPA00011248 A MX PA00011248A MX PA00011248 A MXPA00011248 A MX PA00011248A
Authority
MX
Mexico
Prior art keywords
radiation
receptor tyrosine
inhibitors
treatment
growth factor
Prior art date
Application number
MXPA00011248A
Other languages
Spanish (es)
Inventor
Harlan W Waksal
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of MXPA00011248A publication Critical patent/MXPA00011248A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A method to inhibit the growth of tumors in human patients, comprising treating the human patients with an effective amount of a combination of radiation and a non-radiolabeled protein receptor tyrosine kinase inhibitor, the overexpression of which can lead to tumorigenesis.
MXPA00011248A 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. MXPA00011248A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7961298A 1998-05-15 1998-05-15
US8561398P 1998-05-15 1998-05-15
US20613898A 1998-12-07 1998-12-07
PCT/US1999/010741 WO1999060023A1 (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
MXPA00011248A true MXPA00011248A (en) 2004-09-06

Family

ID=27373511

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00011248A MXPA00011248A (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.

Country Status (14)

Country Link
EP (1) EP1080113A4 (en)
JP (1) JP2002515511A (en)
KR (1) KR20010071271A (en)
CN (1) CN1314917A (en)
AU (1) AU4079999A (en)
BR (1) BR9910511A (en)
CA (1) CA2332331A1 (en)
CZ (1) CZ20004224A3 (en)
HK (1) HK1040720A1 (en)
IL (1) IL139707A0 (en)
MX (1) MXPA00011248A (en)
PL (1) PL348634A1 (en)
SK (1) SK17282000A3 (en)
WO (1) WO1999060023A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6599912B1 (en) 1999-06-03 2003-07-29 Jessie L. -S. Au Methods and compositions for modulating cell proliferation and cell death
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
EP1311291A4 (en) * 2000-08-09 2007-07-25 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
CU22979A1 (en) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF TUMORS OVER-EXPRESSING RECEPTORS WITH KINASE ACTIVITY IN TYPOSINE WASTE
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
DK1487856T3 (en) 2002-03-04 2010-10-18 Imclone Llc KDR-specific human antibodies and their use
MXPA04009542A (en) * 2002-04-02 2005-01-25 Pharmacia Italia Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy.
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
WO2005016970A2 (en) 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP2389953A1 (en) 2003-06-09 2011-11-30 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
MXPA06001634A (en) 2003-08-13 2006-04-28 Pfizer Prod Inc Modified human igf-1r antibodies.
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
US7598350B2 (en) * 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
AU2005249206A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an EGFR-inhibitor
MX2007006640A (en) 2004-12-03 2007-06-19 Schering Corp Biomarkers for pre-selection of patients for anti-igf1r therapy.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
CN101613409B (en) 2005-06-17 2014-06-04 英克隆有限责任公司 PDGFR-alpha antibody
ES2374450T3 (en) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC ANTI-BANGEOUS RESPONSE BIOLOGICAL MARKERS FOR KINNER INHIBITORS OF THE GROWTH FACTOR RECEIVER 1 SIMILAR TO INSULIN.
DK1940881T3 (en) * 2005-10-11 2017-02-20 Amgen Res (Munich) Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
NZ574580A (en) 2006-08-21 2011-12-22 Hoffmann La Roche Her2 tumor therapy with an anti-vegf antibody
EP3248617A3 (en) 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US20100183615A1 (en) * 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
KR101234436B1 (en) 2007-09-05 2013-02-18 로슈 글리카트 아게 Combination therapy with type i and type ii anti-cd20 antibodies
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AR071891A1 (en) 2008-05-30 2010-07-21 Imclone Llc ANTI-FLT3 HUMAN ANTIBODIES (THIROSINE KINASE 3 RECEPTOR HUMAN FMS TYPE)
UA104868C2 (en) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Method for treating patient having neoplastic tumor according to predicted reaction
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
JP2012520893A (en) 2009-03-18 2012-09-10 オーエスアイ・ファーマシューティカルズ，エルエルシー Combination cancer treatment comprising administration of an EGFR inhibitor and an IGF-1R inhibitor
TW201544123A (en) 2009-03-20 2015-12-01 Genentech Inc Anti-HER antibodies
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
AR075982A1 (en) 2009-03-31 2011-05-11 Roche Glycart Ag COMBINATION THERAPY OF A AFUCOSILATED ANTIBODY AND ONE OR MORE OF THE SELECTED CYTOKINS OF GM-CSF HUMAN, M-CSF HUMAN AND / OR IL-3 HUMAN AND COMPOSITION
TWI409079B (en) 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with bendamustine
EP2464380A1 (en) 2009-08-14 2012-06-20 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011112953A2 (en) 2010-03-11 2011-09-15 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CA2795544A1 (en) 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
AR082693A1 (en) 2010-08-17 2012-12-26 Roche Glycart Ag COMBINATION THERAPY OF AN ANTI-CD20 AFUCOSILATED ANTIBODY WITH AN ANTI-VEGF ANTIBODY
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
CN103261229A (en) 2010-12-16 2013-08-21 罗切格利卡特公司 Combination therapy of an afucosylated CD20 antibody with a MDM2 inhibitor
MX2013008833A (en) 2011-02-02 2013-12-06 Amgen Inc Methods and compositons relating to inhibition of igf-1r.
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
KR102001686B1 (en) 2011-04-07 2019-07-18 암젠 인크 Novel egfr binding proteins
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
ES2723827T3 (en) 2011-11-11 2019-09-02 Univ Duke Combination drug therapy for the treatment of solid tumors
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
WO2013124419A1 (en) 2012-02-23 2013-08-29 U3 Pharma Gmbh Her3 inhibitor for modulating radiosensitivity
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR102158467B1 (en) 2012-09-07 2020-09-25 제넨테크, 인크. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
AR094403A1 (en) 2013-01-11 2015-07-29 Hoffmann La Roche ANTI-HER3 ANTIBODY COMBINATION THERAPY
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
MA39776A (en) 2014-03-24 2017-02-01 Hoffmann La Roche Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
BR112017028012A2 (en) 2015-07-07 2018-08-28 Genentech Inc THERAPY COMBINED WITH AN ANTIBODY-ANTI-HER2 DRUG CONJUGATE AND A BCL-2 INHIBITOR
CA3006743A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
EP3405194A1 (en) 2016-01-18 2018-11-28 Institut National de la Sante et de la Recherche Medicale (INSERM) The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse
CN116333130A (en) 2016-05-24 2023-06-27 英斯梅德股份有限公司 Antibodies and methods of making the same
JP2020528061A (en) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy with BET inhibitor, Bcl-2 inhibitor and anti-CD20 antibody
CN110891608A (en) 2017-07-26 2020-03-17 豪夫迈·罗氏有限公司 Combination therapy with BET inhibitors and Bcl-2 inhibitors
TW201920282A (en) * 2017-09-29 2019-06-01 中國大陸商上海藥明生物技術有限公司 Bispecific antibodies against EGFR and PD-1
WO2019201882A1 (en) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a proteasome inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
JPH11507535A (en) * 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド Antibodies and antibody fragments that suppress tumor growth
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
IL139707A0 (en) 2002-02-10
CZ20004224A3 (en) 2002-02-13
HK1040720A1 (en) 2002-06-21
BR9910511A (en) 2001-11-20
JP2002515511A (en) 2002-05-28
EP1080113A4 (en) 2002-04-17
CA2332331A1 (en) 1999-11-25
SK17282000A3 (en) 2002-04-04
CN1314917A (en) 2001-09-26
EP1080113A1 (en) 2001-03-07
AU4079999A (en) 1999-12-06
WO1999060023A1 (en) 1999-11-25
KR20010071271A (en) 2001-07-28
PL348634A1 (en) 2002-06-03

Similar Documents

Publication Publication Date Title
MXPA00011248A (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
ATE339957T1 (en) USE OF EGFR TYROSINE KINASE INHIBITORS TO TREAT BREAST CANCER
EP2042194A3 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
AU3216895A (en) Immunoconjugates comprising tyrosine kinase inhibitors
TR200102707T2 (en) Preparing and using radium-223 for contaminated target tissues for pain relief, bone cancer therapy and healthy bone surface retention.
MD1616G2 (en) Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment
BG108214A (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
MD1632G2 (en) Bicyclic compounds, method of inhibiting the tyrosine kinases receptors as epidermal growth factor, pharmaceutical composition, methods of preventing blastocyte implantation and treatment of mammals
HUP0003194A3 (en) Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
GR20010300033T1 (en) Raf kinase inhibitors
FI972492A0 (en) Imidazole derivatives as inhibitors of protein kinases, in particular EGF-R tyrosine kinase
EP0768885A4 (en) Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
MY130363A (en) "pyrrole substituted 2-indolinone protein kinase inhibitors"
HK1035188A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
MY133403A (en) Tetracycline derivatives and methods of use thereof
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
TNSN04015A1 (en) Combination therapy for the treatment of cancer
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
GB2370961B (en) System and method for optimizing radiation treatment with an intensity modulating multi-leaf collimator
GB9824437D0 (en) Gene therapy
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers